Study limitation reported by the research below: “Cost savings are modeled hypothetically using 2024 U.S. Medicare rates and do not include geographic variation, clinician time, downstream treatment costs, or the economic consequences of misclassification including ARIA risk from false-positive DMT eligibility.”